View Older Stories View More Recent Stories

Nov 29, 2017 05:01PM Amgen (AMGN) Says Aimovig Phase 3 STRIVE Data Published in NEJM Shows Significant, Sustained Efficacy In Migraine Prevention
Nov 29, 2017 05:00PM Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
Nov 27, 2017 04:00PM Amgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
Nov 17, 2017 09:00AM Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients
Nov 13, 2017 04:31PM Amgen (AMGN) Says New Analyses Presented at AHA 2017 Show Repatha Significantly Reduced CV in Patients With PAD And In Patients With History of Heart Attacks
Nov 13, 2017 04:00PM New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks
Nov 10, 2017 07:29AM Amgen (AMGN), Allergan (AGN) Receive Positive CHMP Opinion For ABP 215 for The Treatment of Certain Types Of Cancer
Nov 10, 2017 07:29AM Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Nov 10, 2017 07:27AM Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Nov 6, 2017 09:01AM Amgen (AMGN) Announces New Analyses Of High-Risk Patient Subgroups From Repatha Cardiovascular Outcomes Study At AHA
Nov 6, 2017 09:00AM Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017
Nov 2, 2017 05:27PM Amgen (AMGN), Novartis (NVS) Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program
Nov 2, 2017 04:30PM Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program
Oct 31, 2017 02:30AM Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
Oct 26, 2017 09:27AM Pre-Open Movers 10/26: (MNOV) (BWLD) (TWTR) Higher; (IDRA) (CELG) (NTRI) Lower (more...)
Oct 25, 2017 04:01PM Amgen Reports Third Quarter 2017 Financial Results
Oct 24, 2017 04:36PM Amgen (AMGN) Names Wanda Austin to Board
Oct 24, 2017 04:34PM Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors
Oct 24, 2017 04:00PM Amgen Announces 2017 Fourth Quarter Dividend
Oct 24, 2017 09:00AM Award-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch 'At Home With Joan' To Empower Patients Battling Cancer
Oct 23, 2017 04:02PM Amgen (AMGN) Says Phase 3 A.R.R.O.W. Study of Once-Weekly KYPROLIS Regimen Meet Primary Endpoint of Progression-Free Survival In R/R Multiple Myeloma Patients
Oct 23, 2017 04:00PM Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Oct 20, 2017 04:00PM Amgen Announces Webcast of 2017 Third Quarter Financial Results
Oct 16, 2017 04:00PM Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes
Oct 12, 2017 09:00AM Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons
Oct 9, 2017 04:01PM Amgen (AMGN) Says FDA Accepted sBLA For Prolia In Glucocorticoid-Induced Osteoporosis
Oct 9, 2017 04:00PM FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis
Oct 6, 2017 04:01PM Amgen And LabCentral Open Nomination Process For Lab Residency
Oct 5, 2017 04:35PM Amgen (AMGN) Announces First Randomized Study To Evaluate IMLYGIC (Talimogene Laherparepvec) Published in Journal Of Clinical Oncology
Oct 5, 2017 04:30PM First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
Oct 5, 2017 12:33PM Sanofi (SNY) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:31PM Regeneron (REGN) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 4, 2017 08:00AM Loncar Cancer Immunotherapy Index Announces Merger Replacements
Oct 3, 2017 04:05PM Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
Sep 28, 2017 08:01AM AbbVie (ABBV) Reports Resolution of HUMIRA Patent Disputes with Amgen (AMGN)
Sep 28, 2017 08:00AM Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA™
Sep 26, 2017 04:02PM Amgen (AMGN) and Simcere Pharmaceutical Group Report Strategic Collaboration to Co-Develop And Commercialize Biosimilars In China
Sep 26, 2017 04:00PM Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
Sep 25, 2017 09:07AM Amgen (AMGN) Reaffirms its 2017 Guidance
Sep 25, 2017 09:00AM Amgen Provides Update On Hurricane Maria
Sep 22, 2017 04:53PM Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts
Sep 15, 2017 05:48AM Amgen (AMGN) Reports New Analysis Demonstrating Repatha (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
Sep 15, 2017 04:32AM New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
Sep 14, 2017 02:57PM Amgen (AMGN), Allergan (AGN) Confirm FDA Approval of MVASI For Treatment of Five Types of Cancer
Sep 14, 2017 02:54PM FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
Sep 11, 2017 04:15PM Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
Sep 11, 2017 04:04PM Amgen (AMGN), UCB Announce EVENITY ARCH Study Results Published in NEJM
Sep 11, 2017 04:00PM EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
Sep 11, 2017 05:46AM Amgen (AMGN) & Allergen (AGN) Report Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980
Sep 9, 2017 03:00AM Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
View More Recent Stories View Older Stories